Background:

Prostate cancer is one of the main oncologic pathologies in males. Close to 1 out of every 7 men are diagnosed with prostate cancer at some point in their lives. Early diagnosis is currently the priority of all screening methods.

Clinical report:

A 63-year-old man had a prostate-specific antigen value of 8.2 ng/ml, a non-suspicious digital rectal examination, and a previous prostate biopsy that was negative for malignant pathology. He was referred for a multiparametric magnetic resonance imaging scan of the prostate, which identified a PI-RADS 4 pattern. Magnetic resonance imaging/transrectal ultrasound (MRI/TRUS) image-guided fusion biopsy with the Artemis system was performed. Four cores were taken from the suspicious site, resulting in the diagnosis of adenocarcinoma of the prostate, with a Gleason score of 7 (4+3).

Conclusion:

Through the aid of the Artemis MRI/TRUS image-guided fusion biopsy system in prostate cancer screening, the probability of identifying clinically significant lesions can be increased, the number of cores taken can be reduced, and the probability of identifying prostate cancer in a previously biopsied patient can also be increased, compared with a conventional technique.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )